Список литературы:

1. Берштейн Л.М. Бигуаниды: экспансия в практическую онкологию (прошлое и настоящее). СПб: Эскулап, 2010.

2. Chong CR, Chabner BA. Mysterious metformin // Oncologist. – 2009. - Vol.

3. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression // Nat Rev Cancer. - 2009. – Vol. 9(8). – P.563-575.

4. Dilman V.M., Berstein L.M., Yevtushenko T.P. et al. Preliminary evidence on metabolic rehabilitation of cancer patients // Arch.Geschwulstf. – 1988. – Vol. 58(3). – P.175-183.

5. Дильман В.М. Эндокринологическая онкология. Изд. 2-е. Л.: Медицина,1983.

6. Berstein L.M. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer // Cancer Lett. - 2005. – Vol. 224(2). – P. 203-212.

7. Bailey C., Turner R.H. Metformin // New Engl. J. Med. – 1996. – Vol.334. – P.574-579.

8. Goodwin PJ, Ennis M, Pritchard KI. et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study // J Clin Oncol. – 2002. – Vol. 20(1). – P.42-51.

9. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action // J. Clin. Oncol. – 2009 – Vol. 27(20). – P.3271-3273.

10. Квачевская Ю.О. Особенности рака эндометрия при синдроме инсулинорезистентности // Автореф….канд.мед.наук. СПб. – 2000.

11. Schneider MB, Matsuzaki H, Haorah J. et al. Prevention of pancreatic cancer induction in hamsters by metformin // Gastroenterology. – 2001. – Vol. 120(5). – P.1263-1270.

12. Anisimov VN, Berstein LM, Egormin PA et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice // Exp Gerontol. – 2005. – Vol. 40(8-9). - P.685-693.

13. Evans JM, Donnelly LA, Emslie-Smith AM. et al. Metformin and reduced risk of cancer in diabetic patients // BMJ. – 2005.

14. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure // Diabetologia. – 2010. – Vol.53(8). – P.1631-1637.

15. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes // Diabetologia. – 2009. – Vol. 52(9). – P.1766-1777.

16. Landman GW, Kleefstra N, van Hateren KJ. et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 // Diabetes Care. – 2010. – Vol. 33(2). – P.322-326.

17. Libby G., Donnely LA, Donnan PT. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes // Diabetes Care. – 2009. – Vol.32. – P.1620-1625.

18. Giovannucci E, Harlan DM, Archer MC. et al. Diabetes and cancer: a consensus report // CA Cancer J Clin. – 2010. – Vol. 60(4). – P.207-221.

19. Caraci F, Chisari M, Frasca G. et al. Effects of phenformin on the proliferation of human tumor cell lines // Life Sci. – 2003. – Vol. 74(5). – P.643-650.

20. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer // Clin Cancer Res. – 2010. - Vol. 16(6). – P.1695-1700.

21. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission // Cancer Res. – 2009. - Vol. 69(19). – P. 7507-7511.

22. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review // Endocr Rev. –2009. –Vol. 30(1).–P.1-50.

23. Muti P, Berrino F, Krogh V. et al. Metformin, diet and breast cancer: an avenue for chemoprevention // Cell Cycle – 2009. – Vol. 8(16). – P.2661.

24. Jiralerspong S., Palla SL, Giordano SH. et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer // J.

25. Martin-Castillo B, Dorca J, Vazquez-Martin A. et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology // Ann. Oncol. – 2010. – Vol. 21(1). – P.187-189.

26. Berstein LM, Yue W., Wang J.P., Santen R.J. Separate and combined actions of tamoxifen and metformin in hormone resistant breast cancer cells // Breast Cancer Res Treat. 2010, Aug 4. [Epub ahead of print]

27. Colquhoun A, Venier N.A., Fleshner N.E. et al. Utilizing metformin to enhance the efficacy of androgen deprivation therapy in the treatment of prostate cancer // Proc. AACR Meeting, Washington, DC – 2010. - Abstract 1799.

28. Берштейн Л.М., Бояркина М.П., Туркевич Е.А. и др. Влияние предшествующей терапии сахарного диабета на рецепторный фенотип рака молочной железы: сравнение метформина и препаратов сульфонилмочевины // Вопр. онкол. – 2010. – Т.56(3). – С.312-316.

29. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase // Breast Cancer Res Treat. - 2010, Mar 19. [Epub ahead of print]

30. Rice S, Pellatt L, Ramanathan K. et al. Metformin inhibits aromatase via an ERK (extracellular signal-regulated kinase) - mediated pathway // Endocrinology. – 2009. – Vol.150. – P.4794-4801.

31. Berstein LM, Koskela A, Boyarkina MP, Adlercreutz H. Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin // Neoplasma. – 2010. – Vol. 57(4). – P.333-338.

32. Barba M, Schünemann HJ, Sperati F. et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis // Clin Endocrinol (Oxf). – 2009. – Vol. 70(5). – P.661-670.

33. Jalving M, Gietema JA, Lefrandt JD. et al. Metformin: Taking away the candy for cancer? // Eur. J. Cancer. 2010, Jul 23. [Epub ahead of print]

34. Shu Y, Sheardown SA, Brown C. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action // J. Clin. Invest. – 2007. – Vol. 117(5). – P.1422-1431.